Literature DB >> 17612795

Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method.

Andrew C Hooker1, Christine E Staatz, Mats O Karlsson.   

Abstract

PURPOSE: Population model analyses have shifted from using the first order (FO) to the first-order with conditional estimation (FOCE) approximation to the true model. However, the weighted residuals (WRES), a common diagnostic tool used to test for model misspecification, are calculated using the FO approximation. Utilizing WRES with the FOCE method may lead to misguided model development/evaluation. We present a new diagnostic tool, the conditional weighted residuals (CWRES), which are calculated based on the FOCE approximation.
MATERIALS AND METHODS: CWRES are calculated as the FOCE approximated difference between an individual's data and the model prediction of that data divided by the root of the covariance of the data given the model.
RESULTS: Using real and simulated data the CWRES distributions behave as theoretically expected under the correct model. In contrast, in certain circumstances, the WRES have distributions that greatly deviate from the expected, falsely indicating model misspecification. CWRES/WRES comparisons can also indicate if the FOCE estimation method will improve the results of an FO model fit to data.
CONCLUSIONS: Utilization of CWRES could improve model development and evaluation and give a more accurate picture of if and when a model is misspecified when using the FO or FOCE methods.

Mesh:

Substances:

Year:  2007        PMID: 17612795     DOI: 10.1007/s11095-007-9361-x

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  13 in total

1.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

Authors:  E N Jonsson; M O Karlsson
Journal:  Comput Methods Programs Biomed       Date:  1999-01       Impact factor: 5.428

2.  Assessment of actual significance levels for covariate effects in NONMEM.

Authors:  U Wählby; E N Jonsson; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

3.  Guidance for industry on Population Pharmacokinetics; availability. Food and Drug Administration, HHS. Notice.

Authors: 
Journal:  Fed Regist       Date:  1999-02-10

4.  Ordinary differential equation PK/PD models using the SAS macro NLINMIX.

Authors:  Andrzej T Galecki; Russell D Wolfinger; Oscar A Linares; Marla J Smith; Jeffrey B Halter
Journal:  J Biopharm Stat       Date:  2004-05       Impact factor: 1.051

5.  Considerations in analyzing single-trough concentrations using mixed-effects modeling.

Authors:  Brian P Booth; Jogarao V S Gobburu
Journal:  J Clin Pharmacol       Date:  2003-12       Impact factor: 3.126

6.  Nonlinear mixed effects models for repeated measures data.

Authors:  M L Lindstrom; D M Bates
Journal:  Biometrics       Date:  1990-09       Impact factor: 2.571

7.  Prediction discrepancies for the evaluation of nonlinear mixed-effects models.

Authors:  France Mentré; Sylvie Escolano
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-11-13       Impact factor: 2.745

8.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

9.  Model-based drug development: the road to quantitative pharmacology.

Authors:  Liping Zhang; Vikram Sinha; S Thomas Forgue; Sophie Callies; Lan Ni; Richard Peck; Sandra R B Allerheiligen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-13       Impact factor: 2.745

10.  Comparison of some practical sampling strategies for population pharmacokinetic studies.

Authors:  E N Jonsson; J R Wade; M O Karlsson
Journal:  J Pharmacokinet Biopharm       Date:  1996-04
View more
  133 in total

1.  Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.

Authors:  Huixin Yu; Neeltje Steeghs; Jacqueline S L Kloth; Djoeke de Wit; J G Coen van Hasselt; Nielka P van Erp; Jos H Beijnen; Jan H M Schellens; Ron H J Mathijssen; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

2.  Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1.

Authors:  Hee-Doo Yoo; Hea-Young Cho; Sang-No Lee; Hwa Yoon; Yong-Bok Lee
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-05-24       Impact factor: 2.745

3.  Population pharmacokinetics and pharmacodynamics of bivalirudin in young healthy Chinese volunteers.

Authors:  Dong-mei Zhang; Kun Wang; Xia Zhao; Yun-fei Li; Qing-shan Zheng; Zi-ning Wang; Yi-min Cui
Journal:  Acta Pharmacol Sin       Date:  2012-06-04       Impact factor: 6.150

4.  Evaluation of graphical diagnostics for assessing goodness of fit of logistic regression models.

Authors:  Venkata V Pavan Kumar; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-12-14       Impact factor: 2.745

5.  Scaling of pharmacokinetics across paediatric populations: the lack of interpolative power of allometric models.

Authors:  Massimo Cella; Catherijne Knibbe; Saskia N de Wildt; Joop Van Gerven; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

6.  Population Pharmacokinetics and Dosing Optimization of Imipenem in Children with Hematological Malignancies.

Authors:  Lei Dong; Xiao-Ying Zhai; Yi-Lei Yang; Li Wang; Yue Zhou; Hai-Yan Shi; Bo-Hao Tang; Yue-E Wu; Fan Yang; Li Wen; Hong-Xiao Kong; Li-Juan Zhi; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

7.  Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis.

Authors:  Hiroyuki Inoue; Yoko Tamaki; Yushi Kashihara; Shota Muraki; Makoto Kakara; Takeshi Hirota; Ichiro Ieiri
Journal:  Br J Clin Pharmacol       Date:  2018-12-06       Impact factor: 4.335

8.  Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs.

Authors:  Soo-Han Lee; Hyun-Ji Kang; Seok-Joon Jin; Do-Yang Park; Yoon-Ji Choi; Byung-Moon Choi; Eun-Kyung Lee; Gyu-Jeong Noh
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-08-24       Impact factor: 2.745

Review 9.  Covariate pharmacokinetic model building in oncology and its potential clinical relevance.

Authors:  Markus Joerger
Journal:  AAPS J       Date:  2012-01-25       Impact factor: 4.009

10.  Amikacin maturation model as a marker of renal maturation to predict glomerular filtration rate and vancomycin clearance in neonates.

Authors:  Wei Zhao; Valérie Biran; Evelyne Jacqz-Aigrain
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.